Skip to main content

Table 3 Toxicity, solubility, drug likeliness accounted by TOPKAT in Discovery Studio 3.1

From: Design, synthesis and in-vitro anti-depressant activity evaluation of some 2-styrylbenzimidazole derivatives

Compound code

ADMET solubility level

ADMET absorption level

ADMET AlogP98

ADMET PSA 2D

Carcinogenicity

Skin irritancy

MS 1

2

0

4.774

43.149

MS 2

1

0

5.095

51.21

MS 3

2

0

2.578

76.831

MS 4

1

0

4.979

43.149

MS 5

1

0

3.664

54.563

MS 6

1

1

6.007

16.609

MS 7

1

1

6.185

16.609

MS 8

1

1

6.269

16.609

MS9

1

0

6.269

16.609

Mild

MS10

1

1

5

19.961

Mild

MS11

2

0

6.192

16.609

Mild

MS12

1

1

3.735

28.891

Mild

MS13

1

0

5.683

19.961

Mild

MS14

1

1

5.504

25.539

Mild

MS15

1

1

6.442

16.609

Mild

MS16

1

1

6.054

16.609

Mild

MS17

0

3

6.513

16.609

Mild

MS18

1

1

7.177

16.609

Mild

MS19

1

0

6.26

16.609

Mild

MS20

2

0

4.909

27.87

Mild

MS21

0

1

3.77

28.891

Mild

MS22

1

0

6.429

16.609

Mild

MS23

1

0

5.52

16.609

Mild

MS24

1

0

4.739

31.664

Mild

MS25

1

1

5.357

16.609

Mild

MS26

1

0

6.007

16.609

Mild

MS27

1

0

5.278

37.424

Mild

MS28

1

0

5.278

37.424

Mild

MS29

1

0

5.504

25.539

Mild

MS30

1

0

4.963

19.961

Mild

MS31

2

0

5.215

19.961

Mild

MS32

2

0

4.626

43.149

Mild

MS33

1

0

4.003

23.314

Mild

MS34

2

0

5.415

59.432

Mild

MS35

1

1

4.781

43.149

Mild

MS36

1

0

6.185

16.609

Mild

MS37

2

0

5.581

51.21

Mild

MS38

2

0

4.37

27.87

Mild

MS39

1

1

4.162

16.609

Mild

MS40

1

0

6.192

23.314

Mild